Drug-Coated Balloons vs. Conventional Angioplasty Below the Knee

This meta-analysis is an update on the role of drug-coated balloons in the treatment of infrapopliteal arterial disease, a difficult pathology for all strategies.

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

The primary endpoint of this meta-analysis was treated lower limb salvage at 12 months. The secondary endpoints included survival at 12 months, amputation free survival, restenosis, and target lesion repeat revascularization rate.

This analysis included 10 studies and a total of 1593 patients, even though study quality was moderate to low, according to the standards.

The treated limb salvage rate was 94% with drug-coated balloons vs. 95.7% with conventional angioplasty, which is not a significant difference.


Read also: Crest-2 Registry: Carotid PCI Presents Low Rates of Death and Stroke.


The survival rate at one year was 89.8% vs. 92.9%, which is not a significant difference either.

An analysis of the 4 most uniform studies showed a 32.9% rate of restenosis with drug-coated balloons vs. a 62% rate with conventional angioplasty. This difference seems significant, but there is great dispersion in the confidence interval (odds ratio [OR]: 2.87; 95% confidence interval [CI]: 0.83 to 9.92).

The amputation free survival rate was 82.5% with drug-coated balloons vs. 88.7% with conventional angioplasty (OR: 0.79; 95% CI: 0.23 to 2.75).


Read also: How Much Should We Exercises to Reduce Mortality?


There were no significant differences in any of the studied endpoints.

Conclusion

Based on this systematic review and meta-analysis, there are no significant differences in terms of lower limb salvage, survival, restenosis, target lesion revascularization, or amputation free survival between angioplasty with drug-coated balloons and conventional angioplasty in infrapopliteal arterial disease.

Original Title: Drug Coated Balloon Angioplasty vs. Standard Percutaneous Transluminal Angioplasty in Below the Knee Peripheral Arterial Disease: A Systematic Review and Meta-Analysis.

Reference: Jetty Ipema et al. Eur J Vasc Endovasc Surg, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...